01—Abstract
Summary
Summary of the 10-Q filed May 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported first-quarter 2026 net income of $197.9 milliona, or $1.91 per diluted share, compared with $7.9 million, or $0.08 per diluted share, in the first quarter of 2025.
Total revenues rose to $814.5 millionb from $572.6 million, driven by net product sales of $811.0 million. INGREZZA net product sales were $656.9 million versus $545.2 million a year earlier, and CRENESSITY net product sales were $153.3 million versus $14.5 million. Operating income was $193.4 million, up from $23.6 million, and the period included a $28.6 million pre-tax gain on the January 2026 sale of Neurocrine Group Limited to Immedica Pharma AB for $63.2 million in cash.
Liquidity remained substantial, with total cash, cash equivalents and marketable securities of $2,647.2 millionc at March 31, 2026, versus $2,543.4 million at December 31, 2025, and working capital of $1,604.4 million. Cash flow from operating activities was $145.8 million. The company repurchased 0.4 million shares for $56.0 million during the quarter and had $276.3 million remaining under its 2025 Repurchase Program.
The most significant subsequent event is the pending acquisition of Soleno Therapeutics, Inc. for an equity value of approximately $2.9 billiond, through a $53.00 per share cash tender offer commenced April 20, 2026. The Hart-Scott-Rodino waiting period expired April 27, 2026, and the company expects to fund the transaction with cash on hand and expects closing in the second quarter of 2026, subject to a tender of at least a majority of Soleno shares and other customary conditions. The filing also discloses an ongoing U.S. Department of Justice civil investigative demand related to INGREZZA sales and marketing, and patent litigation with Zydus over INGREZZA SPRINKLE.
02—Key points
Key Highlights
- Net income of $197.9 million ($1.91 diluted EPS) versus $7.9 million ($0.08) in Q1 2025.
- Total revenues of $814.5 million, up from $572.6 million; net product sales of $811.0 million.
- INGREZZA net product sales of $656.9 million (vs. $545.2 million) and CRENESSITY net product sales of $153.3 million (vs. $14.5 million).
- Operating income of $193.4 million, including a $28.6 million pre-tax gain on the sale of Neurocrine Group Limited.
- Total cash, cash equivalents and marketable securities of $2,647.2 million at March 31, 2026, compared with $2,543.4 million at December 31, 2025.
- Pending acquisition of Soleno Therapeutics for approximately $2.9 billion in cash; HSR waiting period expired April 27, 2026, with closing expected in Q2 2026.
- Ongoing DOJ civil investigative demand related to INGREZZA sales and marketing, and Paragraph IV patent litigation with Zydus over INGREZZA SPRINKLE.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2026, Neurocrine Biosciences kept $0.24.
- Revenue$814.5M100.0%
- Cost of revenue−$13.8M1.7%
- Gross profit$800.7M98.3%
- Operating costs−$607.3M74.6%
- Operating income$193.4M23.7%
- Interest, other & tax$4.5M0.6%
- Net income$197.9M24.3%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2026filed May 5, 2026Financial Statements
Q1 FY2026 against Q1 FY2025
| Line item | Q1 FY2026Q1 FY2025 | Change |
|---|---|---|
| Revenue | $814.50M$572.60M | +42.2% |
| Cost of Revenue | $13.80M$9.20M | +50.0% |
| Gross Profit | $800.70M$563.40M | +42.1% |
| SG&A Expenses | $318.50M$276.50M | +15.2% |
| Operating Expenses | $621.10M$549.00M | +13.1% |
| Operating Income | $193.40M$23.60M | +719.5% |
| Net Income | $197.90M$7.90M | +2405.1% |
| EPS (Basic) | $1.97$0.08 | +2362.5% |
| EPS (Diluted) | $1.91$0.08 | +2287.5% |
| Shares Outstanding (Basic) | 100.50M99.70M | +0.8% |
| Shares Outstanding (Diluted) | 103.40M102.50M | +0.9% |
05—Questions
Frequently Asked Questions
How did revenue and profitability change year over year?
Total revenues increased to $814.5 million from $572.6 million, and net income increased to $197.9 million from $7.9 million. Operating income rose to $193.4 million from $23.6 million. Growth was primarily driven by CRENESSITY and INGREZZA net product sales, and the quarter also benefited from a $25.3 million unrealized gain on equity investments versus a $30.6 million loss a year earlier.
What is the status of the Soleno Therapeutics acquisition?
Neurocrine entered into a merger agreement on April 5, 2026 to acquire Soleno for $53.00 per share in cash, an equity value of approximately $2.9 billion. The tender offer commenced April 20, 2026, and the HSR waiting period expired April 27, 2026. Completion still requires the tender of at least a majority of outstanding Soleno shares and other customary closing conditions. The company expects to fund the deal with cash on hand and expects it to close in the second quarter of 2026.
How will the Soleno acquisition affect the company's cash position?
The filing states that if the acquisition is consummated, it would significantly reduce cash, cash equivalents and investment balances. The company also plans to take on a modest amount of pre-payable debt to preserve additional liquidity. Because the agreement was signed after the balance sheet date, no related amounts are recognized in the March 31, 2026 financial statements.
What legal and regulatory matters are disclosed?
In August 2025 the company received a civil investigative demand from the U.S. Department of Justice related to sales and marketing of INGREZZA, and it is cooperating; the timing and outcome are uncertain. The company is also litigating against Zydus over a Paragraph IV certification for a generic INGREZZA SPRINKLE ANDA. The company believes none of its pending claims is likely to have a material adverse effect.
What drove the increase in operating expenses?
Total operating expenses rose to $621.1 million from $549.0 million. Selling, general and administrative expense increased to $318.5 million from $276.5 million, reflecting commercial organization investment and recent sales team expansion. Research and development expense increased to $296.2 million from $263.2 million, and acquired in-process R&D rose to $21.2 million from $0.1 million, partly offset by lower milestone expense of $22.6 million versus $45.4 million.
06—Continue